1 Matching Annotations
  1. Feb 2022
  2. www.medrxiv.org www.medrxiv.org
    https://medrxiv.org/cgi/content/10.1101/2022.02.15.22270948
    1
    1. jackiekrauss 21 Feb 2022

      Regev-Yochay, G., Gonen, T., Gilboa, M., Mandelboim, M., Indenbaum, V., Amit, S., Meltzer, L., Asraf, K., Cohen, C., Fluss, R., Biber, A., Nemet, I., Kliker, L., Joseph, G., Doolman, R., Mendelson, E., Freedman, L. S., Harats, D., Kreiss, Y., & Lustig, Y. (2022). 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC (p. 2022.02.15.22270948). medRxiv. https://doi.org/10.1101/2022.02.15.22270948

      is:preprint lang:en COVID-19 Omicron variant Immunogenicity efficacy safety mRNA vaccine fourth dose clinical intervention symptomatic disease healthcare-workers breakthrough infection high viral load antibody titer next generation vaccine development
    Visit annotations in context

    Tags

    Annotators

    URL

    medrxiv.org/content/10.1101/2022.02.15.22270948v1.full.pdf